Replies to post #373456 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

It would seem reasonable to have a full data analysis of the PDD trial to use in guiding the design of the PD trial. We have seen the effects of making a small change in the endpoint definitions has had on the share price. Getting the PD trail design right from the beginning is pretty important.

[abew4me]

QUOTE: "I for one cannot think of any valid reason why the p3 trial for Parkinsons was not started last spring."

I can think of one possibility: Our BP partner.

If Dr. M is going to partner with BP to promote A2-73 for AD around the world, it just makes sense that he's going to include Parkinson's Disease as well...because they're the two largest CNS diseases in the world.

He knows that our BP partner can get it through the FDA much faster than we can.

Assuming everything goes well, I can see this partnership leading to another deal to promote A2-73 as a prophylactic on a worldwide basis, too.

While we're collecting royalties on our BP partnership deals, Anavex can focus on the rare disease segment...which is what I believe TGD really wants to do anyway.

(I originally wrote about this in my post #371885 on August 27th)

All comments are just my opinion. Do your own DD.